These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Comi G; Martinelli V; Rodegher M; Moiola L; Bajenaru O; Carra A; Elovaara I; Fazekas F; Hartung HP; Hillert J; King J; Komoly S; Lubetzki C; Montalban X; Myhr KM; Ravnborg M; Rieckmann P; Wynn D; Young C; Filippi M; Lancet; 2009 Oct; 374(9700):1503-11. PubMed ID: 19815268 [TBL] [Abstract][Full Text] [Related]
45. Copolymer 1 (glatiramer acetate) in relapsing forms of multiple sclerosis: open multicenter study of alternate-day administration. Flechter S; Kott E; Steiner-Birmanns B; Nisipeanu P; Korczyn AD Clin Neuropharmacol; 2002; 25(1):11-5. PubMed ID: 11852290 [TBL] [Abstract][Full Text] [Related]
46. [Rare and clinically relevant adverse reactions following subcutaneous administration of glatiramer acetate]. Sevilla Ortiz M; Martínez Martínez L; Piñeiro Corrales G Farm Hosp; 2011; 35(3):160-1. PubMed ID: 21441052 [No Abstract] [Full Text] [Related]
47. Impact of warm compresses on local injection-site reactions with self-administered glatiramer acetate. Jolly H; Simpson K; Bishop B; Hunter H; Newell C; Denney D; Oleen-Burkey M J Neurosci Nurs; 2008 Aug; 40(4):232-9. PubMed ID: 18727339 [TBL] [Abstract][Full Text] [Related]
48. [Possibilities and limits of immunotherapy in multiple sclerosis. Inflammatory and degenerative aspects of the disease require a new pathogenetic concept]. Kornhuber ME; Zierz S Nervenarzt; 2003 Jun; 74(6):537-8; discussion 539. PubMed ID: 12799792 [No Abstract] [Full Text] [Related]
49. Evidence for use of glatiramer acetate in multiple sclerosis. Caramanos Z; Arnold DL Lancet Neurol; 2005 Feb; 4(2):74-5; discussion 76-7. PubMed ID: 15664538 [No Abstract] [Full Text] [Related]
50. Evidence for use of glatiramer acetate in multiple sclerosis. Comi G; Hartung HP; Martinelli Boneschi F Lancet Neurol; 2005 Feb; 4(2):75-6; discussion 76-7. PubMed ID: 15664539 [No Abstract] [Full Text] [Related]
51. Glatiramer acetate during early pregnancy: A prospective cohort study. Herbstritt S; Langer-Gould A; Rockhoff M; Haghikia A; Queisser-Wahrendorf A; Gold R; Hellwig K Mult Scler; 2016 May; 22(6):810-6. PubMed ID: 26754804 [TBL] [Abstract][Full Text] [Related]
52. Severe anaphylactic reaction to glatiramer acetate with specific IgE. Rauschka H; Farina C; Sator P; Gudek S; Breier F; Schmidbauer M Neurology; 2005 Apr; 64(8):1481-2. PubMed ID: 15851756 [No Abstract] [Full Text] [Related]
58. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. Fox RJ; Miller DH; Phillips JT; Hutchinson M; Havrdova E; Kita M; Yang M; Raghupathi K; Novas M; Sweetser MT; Viglietta V; Dawson KT; N Engl J Med; 2012 Sep; 367(12):1087-97. PubMed ID: 22992072 [TBL] [Abstract][Full Text] [Related]